SpinalCyte Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
May. 17, 2018
HOUSTON--(BUSINESS WIRE)--May 17, 2018--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts (HDFs), today announced poster presentations highlighting a recent double-blind, placebo controlled human trial of CybroCell™ HDFs to treat degenerative disc disease along with Superior Immune Modulation for Arthritis and Treatment of Acute Liver Failure.
Poster Presentation Details:
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 25 U.S. and international issued patents and has filed for an additional 48 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005929/en/
CONTACT: SpinalCyte, LLC
Dan Keeney, APR, 832.467.2904
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: SpinalCyte, LLC
Copyright Business Wire 2018.
PUB: 05/17/2018 11:07 AM/DISC: 05/17/2018 11:07 AM